Ocata Therapeutics Inc fka OCAT

[juk]

Rocks,

****ACTC's IND filing and prior research is also based on NIH approved cell line H9**********{ON TARGET AND ON POINT!!}

Your VERY VALID and BY FAR The BEST Point made in the past 3 months on Why I am VERY confident that Advanced Cell's IND for its RPE will be excepted and allowed to move forward. Good job man! The precedent has already been established with Geron. I can also theorize that it is in the best interest of the Stem Cell Sector for Geron to "share" its IND with Advanced to ensure what worked and what did not work in the give and take prior in the approval process? Do you think Geron may have helped/schooled Advanced?

Heah do You know what the time table was from the time Geron submitted its IND until it was ok'd back in Jan 09? I am thinking it may get/secure a faster approval due to the fact of how much of a priority Stem Cell research is too BO?

thanks

juk